Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment

被引:46
作者
Masumi, A
Ozato, K
机构
[1] Natl Inst Infect Dis, Dept Safety Res Biol, Tokyo 2080011, Japan
[2] NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.M101707200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interferon regulatory factor-2 (IRF-2) is at transcription factor of the IRF family that represses interferon-mediated gene expression. In the present study, we show that human monocytic U937 cells express truncated forms of IRF-2 containing the DNA binding do main but lacking much of the C-terminal regulatory domain. U937 cells are shown to respond to phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to induce expression of histone acetylases p300 and p300/CBP-associated factor (PCAF), In addition, TPA treatment led to the appearance of full-length IRF-2, along with a reduction of the truncated protein. interestingly, full-length IRF-2 in TPA-treated U937 cells occurred as a complex with p300 as well as PCAF and was itself acetylated. Consistent with these results, recombinant IRF-2 was acetylated by p300 and to a lesser degree by PCAF in vitro. Another IRF member, IRF-1, an activator of interferon-mediated transcription, was also acetylated in vitro by these acetylases, Finally, we demonstrate that the addition of IRF-2 but not IRF-1. inhibits core histone acetylation by p300 in vitro, The addition of IRF-2 also inhibited acetylation of nucleosomal histones in TPA-treated U937 cells. Acetylated IRF-2 may affect local chromatin structure in vivo by inhibiting core histone acetylation and may serve as a mechanism by which IRF-2 negatively regulates interferon-inducible transcription.
引用
收藏
页码:20973 / 20980
页数:8
相关论文
共 52 条
[1]   Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A [J].
Ait-Si-Ali, S ;
Ramirez, S ;
Barre, FX ;
Dkhissi, F ;
Magnaghi-Jaulin, L ;
Girault, JA ;
Robin, P ;
Knibiehler, M ;
Pritchard, LL ;
Ducommun, B ;
Trouche, D ;
Harel-Bellan, A .
NATURE, 1998, 396 (6707) :184-186
[2]   Regulation of activity of the transcription factor GATA-1 by acetylation [J].
Boyes, J ;
Byfield, P ;
Nakatani, Y ;
Ogryzko, V .
NATURE, 1998, 396 (6711) :594-598
[3]  
Burysek L, 1999, J VIROL, V73, P7334
[4]   Phorbol ester-stimulated phosphorylation of PU.1: Association with leukemic cell growth inhibition [J].
Carey, JO ;
Posekany, KJ ;
deVente, JE ;
Pettit, GR ;
Ways, DK .
BLOOD, 1996, 87 (10) :4316-4324
[5]   Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation [J].
Cheung, P ;
Tanner, KG ;
Cheung, WL ;
Sassone-Corsi, P ;
Denu, JM ;
Allis, CD .
MOLECULAR CELL, 2000, 5 (06) :905-915
[6]   Quantitation of messenger RNA by competitive RT-PCR: a simplified read out assay [J].
Colle, JH ;
Falanga, PB ;
Singer, M ;
Hevin, B ;
Milon, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 210 (02) :175-184
[7]   PU.1, interferon regulatory factor 1, and interferon consensus sequence-binding protein cooperate to increase gp91phox expression [J].
Eklund, EA ;
Jalava, A ;
Kakar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) :13957-13965
[8]   Histone acetylation in chromatin structure and transcription [J].
Grunstein, M .
NATURE, 1997, 389 (6649) :349-352
[9]   Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain [J].
Gu, W ;
Roeder, RG .
CELL, 1997, 90 (04) :595-606
[10]   ANTI-ONCOGENIC AND ONCOGENIC POTENTIALS OF INTERFERON REGULATORY FACTOR-I AND FACTOR-II [J].
HARADA, H ;
KITAGAWA, M ;
TANAKA, N ;
YAMAMOTO, H ;
HARADA, K ;
ISHIHARA, M ;
TANIGUCHI, T .
SCIENCE, 1993, 259 (5097) :971-974